X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CFO Adam S. Mostafa sold 5,417 shares of the firm’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $2.22, for a total transaction of $12,025.74. Following the transaction, the chief financial officer now directly owns 88,279 shares in the […]
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CEO Paula Ragan sold 6,292 shares of the company’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $1.95, for a total value of $12,269.40. Following the completion of the transaction, the chief executive officer now directly owns 557,245 shares […]
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CEO Paula Ragan sold 6,292 shares of the firm’s stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $1.95, for a total transaction of $12,269.40. Following the completion of the transaction, the chief executive officer now directly owns 557,245 shares […]
X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) had its price objective raised by Stifel Nicolaus from $4.00 to $5.00 in a research report sent to investors on Wednesday morning, The Fly reports. XFOR has been the topic of a number of other reports. B. Riley lowered their price objective on shares of X4 Pharmaceuticals from $7.00 […]
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Friday, May 5th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.29 per share for the year, up from their […]